Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer Cell Immunoglobulin-like Receptor 3DL2 (KIR3DL2)
- Target
- KIR3DL2
- Molecular classification
- Receptor, Type I transmembrane glycoprotein, Killer cell immunoglobulin-like receptor (KIR)
01
Overview
KIR3DL2 is an inhibitory receptor expressed on NK cells and γδ T cells. It interacts with MHC class I molecules, including HLA-B27 and HLA-F, to regulate immune responses. Upon ligand binding, its ITIM-containing cytoplasmic tail mediates inhibitory signaling, suppressing effector function. KIR3DL2 also plays a role in delivering CpG DNA to endosomal TLR9, enhancing NK cell activation.
- Other names
- CD158kNKAT4CD158 antigen-like family member K
02
Mechanism of action
ITIM-mediated inhibitory signaling upon ligand binding; TLR9 activation via CpG ODN delivery
03
Biological functions
Inhibitory regulation of NK cell cytotoxicityRegulation of T cell effector functionsInnate immune response modulationCpG DNA delivery to endosomal TLR9
04
Disease associations
Autoimmune disease susceptibility/modulation (e.g., ankylosing spondylitis)Viral infection defenseCancer surveillance
05
Safety considerations
Potential for autoimmunity risk modulation
Beyond the preview
Go deeper on Killer Cell Immunoglobulin-like Receptor 3DL2 (KIR3DL2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Killer Cell Immunoglobulin-like Receptor 3DL2 (KIR3DL2).